Scholar Rock Holding Corp. (SRRK) Misses Q2 EPS by 11c, Revenues Miss

Scholar Rock Holding Corp. (NASDAQ: SRRK) reported Q2 EPS of ($0.65), $0.11 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $6.82 million.

“I am impressed by the execution of the team, and momentum is rapidly building for our lead clinical programs, SRK-015 in SMA and SRK-181 in immuno-oncology, towards several potential value-creation opportunities in late 2020 and throughout 2021,” said Tony Kingsley, President and CEO of Scholar Rock. “Scholar Rock has an exceptional proprietary platform that has yielded multiple clinical candidates that have the potential to transform the lives of patients living with serious diseases, and I look forward to seeing the company continue to drive additional product candidates forward.”

For earnings history and earnings-related data on Scholar Rock Holding Corp. (SRRK) click here.

You May Also Be Interested In

• Morgan Stanley CEO: investment banking momentum is building - Conference Call
• Barrick Gold (GOLD) reported preliminary Q1 production of 940 thousand ounces of gold
• TScan Therapeutics, Inc (TCRX) Provides Clinical Pipeline Update, Highlights Near-Term Priorities